Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative conditions.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative conditions.
This gives us the potential to revolutionise how people think about brain health.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Supporting patient care
- Helping clinicians in their diagnosis
- Differential patterns of brain changes
- Accurately tracking changes
- Proactive brain health
Latest news
New MRI Research Unlocks Earlier Detection of Parkinson’s Disease Microstructural Changes
A groundbreaking study has identified a new way to detect the earliest signs of Parkinson’s disease (PD) using advanced brain imaging. The research (a collaboration involving Oxford Brain Diagnostics and AbbVie) demonstrates that diffusion MRI can reveal microscopic "disarray" in the brain’s cortex years before traditional symptoms appear or standard MRI scans show any change. The study analyzed 143 participants from the Parkinson’s Progression Markers Initiative (PPMI), focusing on individuals with GBA1 and LRRK2 genetic mutations. The findings are significant: non-manifest carriers (those with the gene but no symptoms) already showed measurable microstructural changes in memory-related regions of the brain. In patients where the disease had become manifest, these changes had spread to wider areas of the brain responsible for motor control and complex thinking.
Caladrix and Oxford Brain Diagnostics partner on Phase 1b Trial of C-001, an ABCC1 Activator, in Alzheimer’s Disease
Caladrix and Oxford Brain Diagnostics Ltd Partner to Incorporate Advanced MRI Biomarker (CDM® Cortical Disarray Measurement) as a New Translational Imaging Endpoint in the Forthcoming Phase 1b Trial of C-001, an ABCC1 Activator, in Alzheimer’s Disease. Collaboration integrates next-generation diffusion MRI biomarkers to visualize cortical microstructure and quantify neuroinflammation and neuronal disorganization in vivo. CDM® was granted FDA breakthrough device designation and CDM Insights is FDA 510(k)-cleared. This pioneering imaging biomarker—enables quantitative insight into how ABCC1 activation modulates glial and neuroinflammatory pathways. Integration of CDM® enhances Caladrix’s multidimensional assessment of disease modification in early Alzheimer’s, uniting molecular, fluid, and structural biomarkers
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
Using CDM PerpPD+, a next-generation MRI imaging analysis that quantifies the diffusion components of water molecules that are perpendicular to the cortical gray matter’s minicolumns in the brain (PerpDP+, from Oxford Brain Diagnostics), investigators observed a trend towards slowed neurodegeneration progression in patients receiving XPro1595. These analyses focused on participants with early AD and high inflammatory burden (ADi), including the dose-compliant subgroup.
OBD Guest Speaker series - Dr Henne Holstege
Dr Henne Holstege provides valuable insights into her research on the #100-plus Study: an on-going prospective cohort study of centenarians who self-reported to be cognitively healthy, their first-degree family members and their respective partners
